These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 9436473)

  • 1. [Lipid risk factors of atherosclerosis: who, when, how to treat?].
    Foubert L; Dejager S; Bruckert E; Turpin G
    Ann Endocrinol (Paris); 1997; 58(4):275-82. PubMed ID: 9436473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Hypolipemic agents and prevention of coronary disease].
    Chadarevian R; Bruckert E; Turpin G
    Ann Cardiol Angeiol (Paris); 1997 Feb; 46(2):89-98. PubMed ID: 9137675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Management of atherogenic hyperlipidemia].
    Turpin G; Bruckert E
    Ann Cardiol Angeiol (Paris); 1998 Nov; 47(9):627-32. PubMed ID: 9864558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of hypercholesterolaemia in the patient with diabetes.
    Packard C; Olsson AG
    Int J Clin Pract Suppl; 2002 Jul; (130):27-32. PubMed ID: 12296606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment of hyperlipidemia].
    Yoshino G
    Rinsho Byori; 2002 Mar; 50(3):254-61. PubMed ID: 11985052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dyslipidemias in patients with diabetes mellitus: classification and risks and benefits of therapy.
    Oki JC
    Pharmacotherapy; 1995; 15(3):317-37. PubMed ID: 7667166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Increased triglycerides and/or low HDL cholesterol. A risk factor needing treatment?].
    Steinmetz A
    MMW Fortschr Med; 2002 Aug; 144(31-32):20-3. PubMed ID: 12422724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Hypertricglyceridemia: prognostic impact and treatment options].
    Custodis F; Laufs U
    Dtsch Med Wochenschr; 2011 Jul; 136(30):1533-42. PubMed ID: 21789752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [IV Brazilian Guideline for Dyslipidemia and Atherosclerosis prevention: Department of Atherosclerosis of Brazilian Society of Cardiology].
    Sposito AC; Caramelli B; Fonseca FA; Bertolami MC; Afiune Neto A; Souza AD; Lottenberg AM; Chacra AP; Faludi AA; Loures-Vale AA; Carvalho AC; Duncan B; Gelonese B; Polanczyk C; Rodrigues Sobrinho CR; Scherr C; Karla C; Armaganijan D; Moriguchi E; Saraiva F; Pichetti G; Xavier HT; Chaves H; Borges JL; Diament J; Guimarães JI; Nicolau JC; dos Santos JE; de Lima JJ; Vieira JL; Novazzi JP; Faria Neto JR; Torres KP; Pinto Lde A; Bricarello L; Bodanese LC; Introcaso L; Malachias MV; Izar MC; Magalhães ME; Schmidt MI; Scartezini M; Nobre M; Foppa M; Forti NA; Berwanger O; Gebara OC; Coelho OR; Maranhão RC; dos Santos Filho RD; Costa RP; Barreto S; Kaiser S; Ihara S; Carvalho Td; Martinez TL; Relvas WG; Salgado W;
    Arq Bras Cardiol; 2007 Apr; 88 Suppl 1():2-19. PubMed ID: 17515982
    [No Abstract]   [Full Text] [Related]  

  • 10. [HDL-cholesterol-- active or passive participant in the pathogenesis of atherosclerosis].
    Artenie R; Ungureanu D; Artenie A; Botnariu G; Anisie E
    Rev Med Chir Soc Med Nat Iasi; 2003; 107(2):282-7. PubMed ID: 14755929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Secondary prevention of coronary artery disease with lipid-lowering drugs].
    Delahaye F; De Gevigney G
    Ann Med Interne (Paris); 2001 Apr; 152(3):184-7. PubMed ID: 11431578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [HDL-cholesterol--active or passive participant in the pathogenesis of atherosclerosis? (II)].
    Artenie A; Artenie R; Ungureanu D; Botnariu G; Anisies E; Ionescu SD; Cosovanu A
    Rev Med Chir Soc Med Nat Iasi; 2004; 108(3):503-8. PubMed ID: 15832963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of serum lipid level change on 10-year coronary heart risk distribution estimated by means of seven different coronary risk scores during one-year treatment.
    Kojić NE; Derić M; Dejanović J
    Med Pregl; 2014; 67(7-8):208-15. PubMed ID: 25151760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperlipidemia in children with type 2 diabetes mellitus.
    Taha D
    J Pediatr Endocrinol Metab; 2002 Apr; 15 Suppl 1():505-7. PubMed ID: 12017224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipids in ischemic stroke subtypes.
    Laloux P; Galanti L; Jamart J
    Acta Neurol Belg; 2004 Mar; 104(1):13-9. PubMed ID: 15143957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Coronary disease. Prevention and current therapeutic concepts].
    Fortschr Med Suppl; 1991; 112():1-15. PubMed ID: 9260314
    [No Abstract]   [Full Text] [Related]  

  • 18. Aggressive medical therapy for the prevention and treatment of coronary artery disease.
    Malloy MJ; Kane JP
    Dis Mon; 1998 Jan; 44(1):1-40. PubMed ID: 9457050
    [No Abstract]   [Full Text] [Related]  

  • 19. Hyperlipidemia in long-term survivors of pediatric renal transplantation.
    Sharma AK; Myers TA; Hunninghake DB; Matas AJ; Kashtan CE
    Clin Transplant; 1994 Jun; 8(3 Pt 1):252-7. PubMed ID: 8061364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lifestyle approaches and dietary strategies to lower LDL-cholesterol and triglycerides and raise HDL-cholesterol.
    Katcher HI; Hill AM; Lanford JL; Yoo JS; Kris-Etherton PM
    Endocrinol Metab Clin North Am; 2009 Mar; 38(1):45-78. PubMed ID: 19217512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.